DSpace Repository

Solid Self Nanoemulsifying Drug Delivery System as carrier for the enhancement of bioavailability of Benidipine with Telmisartan

Show simple item record

dc.contributor.author Buddhadev, Sheetal S.
dc.contributor.author Garala, Kevinkumar C.
dc.contributor.author Nariya, Mukeshkumar
dc.contributor.author Rahamathulla, Mohamed
dc.date.accessioned 2024-11-14T09:53:52Z
dc.date.available 2024-11-14T09:53:52Z
dc.date.issued 2023
dc.identifier.citation Buddhadev, S. S., Garala, K. C. Nariya, M.,& Rahamathulla, M. (2023). Solid Self Nanoemulsifying Drug Delivery System as carrier for the enhancement of bioavailability of Benidipine with Telmisartan. European Chemical Bulletin, 12(6), 3253-3265. DOI:10.48047/ecb/2023.12.6.288 en_US
dc.identifier.issn 3253-3265
dc.identifier.uri http://10.9.150.37:8080/dspace//handle/atmiyauni/1473
dc.description.abstract Background: Benidipine (BD) and Telmisartan (TEL), co-administered antihypertensive medicines in the BCS class II group, are characterized by inadequate bioavailability due to restricted water solubility. Self-nano emulsifying drug delivery systems (SNEDDS) offer efficient solubilization for weakly water-soluble medicines due to their ternary ingredients' solubilization and nanonization activity, driven by surfactant and cosolvent. SNEDDS formulations comprise surfactants and cosolvents that facilitate nano droplet dispersion. Objective: This study seeks to investigate the antihypertensive activity of solidified selfnanoemulsifying drug delivery systems (S-SNEDDS) comprising BD and TEL. Methods: Hypertension was produced in rats with oral 10% glucose treatment for three weeks. Animals were grouped: Group 1 as Normal control, Group 2 as Hypertensive control, Group 3 as Hypertensive treated with S-SNEDDS formulation of BD with TEL, and Group 4 as Hypertensive treated with conventional BD-TEL suspension. Rats with a mean blood pressure ≥150 mm Hg were selected. After baseline blood pressure measurement, Group 3 and 4 animals received oral doses of 4 mg BD and 40 mg TEL/kg from optimized S-SNEDDS and pure drug, respectively. Blood pressure was non-invasively monitored using a tail-cuff sensor and Biopack MP36 data gathering system at intervals of 0, 2, 6, 12, and 24 hours. Results and Discussion: In contrast to the hypertensive control group, S-SNEDDS treatment contributed to a progressive blood pressure reduction, peaking at 45 minutes and persisting for 75 minutes. This reduction was statistically different from the control group, demonstrating superior hypertension control compared to BD-TEL suspension. The improved water solubility of BD and TEL due to surfactant presence, together with fast globule dispersion, absolutely contributes to the observed antihypertensive benefits of the SNEDDS formulation. en_US
dc.language.iso en en_US
dc.publisher European Chemical Bulletin en_US
dc.relation.ispartofseries 12;6
dc.subject Benidipine en_US
dc.subject Telmisartan en_US
dc.subject Solidified self-nanoemulsifying drug delivery systems en_US
dc.title Solid Self Nanoemulsifying Drug Delivery System as carrier for the enhancement of bioavailability of Benidipine with Telmisartan en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account